Research ExplorerPublicationsAdministration of bortezomib before and after autologous ste...

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Standard

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. / Neben, Kai; Lokhorst, Henk M; Jauch, Anna; Bertsch, Uta; Hielscher, Thomas; van der Holt, Bronno; Salwender, Hans; Blau, Igor W; Weisel, Katja; Pfreundschuh, Michael; Scheid, Christof; Dührsen, Ulrich; Lindemann, Walter; Schmidt-Wolf, Ingo G H; Peter, Norma; Teschendorf, Christian; Martin, Hans; Haenel, Mathias; Derigs, Hans G; Raab, Marc S; Ho, Anthony D; van de Velde, Helgi; Hose, Dirk; Sonneveld, Pieter; Goldschmidt, Hartmut.

In: BLOOD, Vol. 119, No. 4, 26.01.2012, p. 940-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Neben, K, Lokhorst, HM, Jauch, A, Bertsch, U, Hielscher, T, van der Holt, B, Salwender, H, Blau, IW, Weisel, K, Pfreundschuh, M, Scheid, C, Dührsen, U, Lindemann, W, Schmidt-Wolf, IGH, Peter, N, Teschendorf, C, Martin, H, Haenel, M, Derigs, HG, Raab, MS, Ho, AD, van de Velde, H, Hose, D, Sonneveld, P & Goldschmidt, H 2012, 'Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p', BLOOD, vol. 119, no. 4, pp. 940-8. https://doi.org/10.1182/blood-2011-09-379164

APA

Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., Scheid, C., Dührsen, U., Lindemann, W., Schmidt-Wolf, I. G. H., Peter, N., Teschendorf, C., Martin, H., Haenel, M., Derigs, H. G., ... Goldschmidt, H. (2012). Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. BLOOD, 119(4), 940-8. https://doi.org/10.1182/blood-2011-09-379164

Vancouver

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. BLOOD. 2012 Jan 26;119(4):940-8. https://doi.org/10.1182/blood-2011-09-379164

Bibtex

@article{d623f26f22e24a8494b585abb130b592,
title = "Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p",
abstract = "In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the 2-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared with standard treatment without bortezomib (arm A). For allanalyzed chromosomal aberrations, progression-free survival (PFS) and overall survival (OS) were at least equal or superior in the bortezomib arm compared with the standard arm. Strikingly, patients with del(17p13) benefited the most from the bortezomib-containing treatment: the median PFS in arm A was 12.0 months and in arm B it was 26.2 months (P = .024); the 3 year-OS for arm A was 17% and for arm B it was 69% (P = .028). After multivariate analysis, del(17p13) was an independent predictor for PFS (P < .0001) and OS (P < .0001) in arm A, whereas no statistically significant effect on PFS (P = .28) or OS (P = .12) was seen in arm B. In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13).",
keywords = "Adolescent, Adult, Aged, Antineoplastic Agents, Boronic Acids, Bortezomib, Chromosome Aberrations, Chromosome Deletion, Chromosomes, Human, Pair 17, Cohort Studies, Female, Humans, Induction Chemotherapy, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma, Prognosis, Pyrazines, Smith-Magenis Syndrome, Stem Cell Transplantation, Survival Analysis, Transplantation, Autologous, Young Adult, Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Kai Neben and Lokhorst, {Henk M} and Anna Jauch and Uta Bertsch and Thomas Hielscher and {van der Holt}, Bronno and Hans Salwender and Blau, {Igor W} and Katja Weisel and Michael Pfreundschuh and Christof Scheid and Ulrich D{\"u}hrsen and Walter Lindemann and Schmidt-Wolf, {Ingo G H} and Norma Peter and Christian Teschendorf and Hans Martin and Mathias Haenel and Derigs, {Hans G} and Raab, {Marc S} and Ho, {Anthony D} and {van de Velde}, Helgi and Dirk Hose and Pieter Sonneveld and Hartmut Goldschmidt",
year = "2012",
month = jan,
day = "26",
doi = "10.1182/blood-2011-09-379164",
language = "English",
volume = "119",
pages = "940--8",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

RIS

TY - JOUR

T1 - Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

AU - Neben, Kai

AU - Lokhorst, Henk M

AU - Jauch, Anna

AU - Bertsch, Uta

AU - Hielscher, Thomas

AU - van der Holt, Bronno

AU - Salwender, Hans

AU - Blau, Igor W

AU - Weisel, Katja

AU - Pfreundschuh, Michael

AU - Scheid, Christof

AU - Dührsen, Ulrich

AU - Lindemann, Walter

AU - Schmidt-Wolf, Ingo G H

AU - Peter, Norma

AU - Teschendorf, Christian

AU - Martin, Hans

AU - Haenel, Mathias

AU - Derigs, Hans G

AU - Raab, Marc S

AU - Ho, Anthony D

AU - van de Velde, Helgi

AU - Hose, Dirk

AU - Sonneveld, Pieter

AU - Goldschmidt, Hartmut

PY - 2012/1/26

Y1 - 2012/1/26

N2 - In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the 2-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared with standard treatment without bortezomib (arm A). For allanalyzed chromosomal aberrations, progression-free survival (PFS) and overall survival (OS) were at least equal or superior in the bortezomib arm compared with the standard arm. Strikingly, patients with del(17p13) benefited the most from the bortezomib-containing treatment: the median PFS in arm A was 12.0 months and in arm B it was 26.2 months (P = .024); the 3 year-OS for arm A was 17% and for arm B it was 69% (P = .028). After multivariate analysis, del(17p13) was an independent predictor for PFS (P < .0001) and OS (P < .0001) in arm A, whereas no statistically significant effect on PFS (P = .28) or OS (P = .12) was seen in arm B. In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13).

AB - In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the 2-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared with standard treatment without bortezomib (arm A). For allanalyzed chromosomal aberrations, progression-free survival (PFS) and overall survival (OS) were at least equal or superior in the bortezomib arm compared with the standard arm. Strikingly, patients with del(17p13) benefited the most from the bortezomib-containing treatment: the median PFS in arm A was 12.0 months and in arm B it was 26.2 months (P = .024); the 3 year-OS for arm A was 17% and for arm B it was 69% (P = .028). After multivariate analysis, del(17p13) was an independent predictor for PFS (P < .0001) and OS (P < .0001) in arm A, whereas no statistically significant effect on PFS (P = .28) or OS (P = .12) was seen in arm B. In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13).

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Boronic Acids

KW - Bortezomib

KW - Chromosome Aberrations

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 17

KW - Cohort Studies

KW - Female

KW - Humans

KW - Induction Chemotherapy

KW - Maintenance Chemotherapy

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Prognosis

KW - Pyrazines

KW - Smith-Magenis Syndrome

KW - Stem Cell Transplantation

KW - Survival Analysis

KW - Transplantation, Autologous

KW - Young Adult

KW - Clinical Trial, Phase II

KW - Comparative Study

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1182/blood-2011-09-379164

DO - 10.1182/blood-2011-09-379164

M3 - SCORING: Journal article

C2 - 22160383

VL - 119

SP - 940

EP - 948

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 4

ER -